Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Mov Disord ; 36(9): 2178-2182, 2021 09.
Artigo em Inglês | MEDLINE | ID: mdl-34008894

RESUMO

BACKGROUND: Treatment with sphingosine-1-phosphate (S1P) agonists confers neuroprotective effects in animal models of Parkinson's disease (PD). OBJECTIVES: We assessed the association of serum S1P levels with motor and cognitive symptoms in patients with PD. METHODS: S1P concentrations were analyzed with liquid chromatography-tandem mass spectrometry (LC-MS/MS) in serum of 196 PD patients and in 196 age- and sex-matched controls. Motor (Unified Parkinson's disease rating scale III [UPDRS III], Hoehn and Yahr) and cognitive (Montreal Cognitive Assessment [MoCA]) function were assessed at baseline. Follow-up data was available from 64 patients (median [interquartile range], 513 [381-677] days). RESULTS: S1P levels were lower in PD patients compared with controls, that is 1.75 (1.38-2.07) and 1.90 (1.59-2.18) µmol/L, respectively (P = 0.001). In PD patients, lower S1P concentrations were associated with higher UPDRS III scores and Hoehn and Yahr stage. In the follow-up cohort, S1P concentrations below the median were associated with faster motor decline (hazard ratio: 4.78 [95% CI, 1.98, 11.50]), but not with cognitive worsening. CONCLUSIONS: Our observations reveal an association of S1P with PD. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.


Assuntos
Doença de Parkinson , Cromatografia Líquida , Progressão da Doença , Humanos , Lisofosfolipídeos , Testes de Estado Mental e Demência , Doença de Parkinson/tratamento farmacológico , Índice de Gravidade de Doença , Esfingosina/análogos & derivados , Espectrometria de Massas em Tandem
2.
Mov Disord ; 35(10): 1863-1868, 2020 10.
Artigo em Inglês | MEDLINE | ID: mdl-32557851

RESUMO

BACKGROUND: We assessed if cardiac blood markers are associated with motor and cognitive function in patients with Parkinson's disease (PD). METHODS: High-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were evaluated in 285 PD patients. Furthermore, N-terminal pro-B-type natriuretic peptide levels were analyzed in 570 age, sex and cardiovascular risk factor matched healthy controls. Motor (UPDRS, Hoehn &Yahr) and cognitive function (Montreal Cognitive Assessemtn) were assessed at baseline in all 285 patients and after 1 year in 101 patients. RESULTS: N-terminal pro-B-type natriuretic peptide were significantly increased in 285 PD patients compared with 570 matched healthy controls. In PD patients, increased high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide levels were associated with worse motor function at baseline and also with motor decline after 1 year. N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin I were inversely associated with cognitive function at baseline only in unadjusted models. CONCLUSIONS: Subclinical cardiac microdamage is associated with motor severity in PD patients. © 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.


Assuntos
Doença de Parkinson , Biomarcadores , Cognição , Humanos , Peptídeo Natriurético Encefálico , Doença de Parkinson/complicações , Fragmentos de Peptídeos
3.
Parkinsonism Relat Disord ; 90: 44-48, 2021 09.
Artigo em Inglês | MEDLINE | ID: mdl-34352610

RESUMO

INTRODUCTION: Serum neurofilament light chain (NfL) levels are associated with disease severity in early Parkinson's disease (PD). We assessed the association of serum NfL with motor and cognitive function and decline in advanced PD patients. METHODS: NfL concentrations were analyzed with single molecule array (Simoa) assay in serum of 289 PD patients with advanced disease from the single-center prospective observational biobank study Biomarkers in Parkinson's disease (MARK-PD). Motor and cognitive symptoms were assessed with MDS-UPDRS III, Hoehn&Yahr stages and Montreal Cognitive Assessment (MoCA) at baseline and during 520 [364, 674] days of follow-up. RESULTS: Serum NfL concentrations were associated with Hoehn&Yahr stages. During follow-up, baseline NfL levels were associated with time to cognitive decline in adjusted Cox regression models (hazard ratio: 3.23; 95% CI [1.16, 9.00], P < 0.025). Serum NfL was associated with NT-proBNP in adjusted models linking neuronal and cardiac damage in advanced PD patients. CONCLUSION: In advanced PD patients, serum NfL concentrations are associated with motor function, cognitive decline and subclinical cardiac damage.


Assuntos
Disfunção Cognitiva/sangue , Cardiopatias/sangue , Atividade Motora/fisiologia , Proteínas de Neurofilamentos/sangue , Doença de Parkinson/sangue , Idoso , Biomarcadores/sangue , Cognição/fisiologia , Disfunção Cognitiva/etiologia , Feminino , Coração/fisiopatologia , Cardiopatias/etiologia , Humanos , Masculino , Testes de Estado Mental e Demência , Miocárdio/patologia , Doença de Parkinson/fisiopatologia , Doença de Parkinson/psicologia , Estudos Prospectivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA